ClinicalTrials.gov
ClinicalTrials.gov Menu

OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00081237
Recruitment Status : Completed
First Posted : April 8, 2004
Last Update Posted : June 12, 2013
Sponsor:
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

April 7, 2004
April 8, 2004
June 12, 2013
February 2004
August 2005   (Final data collection date for primary outcome measure)
Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0
Not Provided
Complete list of historical versions of study NCT00081237 on ClinicalTrials.gov Archive Site
  • Safety profile as measured by CTC v3.0
  • Response as measured by RECIST every 6 weeks (2 courses)
  • Pharmacodynamics as measured by drug concentration in the blood during course 1
  • Time to progression as measured by Kaplan Meier and RECIST every 6 weeks during treatment and then every 8 weeks
Not Provided
Not Provided
Not Provided
 
OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer
A Phase I Study of OSI-7904L In Combination With Oxaliplatin In Patients With Advanced Colo-Rectal Cancer

RATIONALE: OSI-7904L may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining OSI-7904L with oxaliplatin may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of OSI-7904L and oxaliplatin in treating patients with refractory or recurrent advanced colorectal cancer.

OBJECTIVES:

Primary

  • Determine the dose-limiting toxicity of OSI-7904L and oxaliplatin in patients with refractory or recurrent advanced colorectal cancer.
  • Determine the maximum tolerated dose of this regimen in these patients.
  • Determine a safe dose for this regimen in these patients.

Secondary

  • Determine the pharmacokinetic profile of this regimen in these patients.
  • Determine the safety profile of this regimen in these patients.
  • Determine the antitumor activity of this regimen in these patients.

OUTLINE: This is a nonrandomized, multicenter, open-label, dose-escalation study.

Patients receive oxaliplatin IV over 2 hours followed by OSI-7904L IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of OSI-7904L and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A maximum of 12 patients receive treatment at the MTD.

Patients are followed every 8 weeks.

PROJECTED ACCRUAL: A total of 3-25 patients will be accrued for this study.

Interventional
Phase 1
Masking: None (Open Label)
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: OSI-7904L
  • Drug: oxaliplatin
Not Provided
Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC; EORTC New Drug Development Group. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008 Apr;61(4):579-85. Epub 2007 May 23.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
Not Provided
Not Provided
August 2005   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed colorectal cancer

    • Radiologic evidence of advanced disease
  • At least 1 measurable lesion at least 20 mm OR at least 10 mm by spiral CT scan

    • Indicator lesions in a previously irradiated field are allowed provided the irradiated lesion has clearly progressed OR a new lesion has developed in the irradiated field
  • Failed 1, and only 1, line of prior chemotherapy for advanced/metastatic disease

    • Disease progression during chemotherapy OR within 6 months after completion of treatment
  • No symptomatic brain metastases meeting any of the following criteria:

    • Unstable
    • Inadequately controlled with fixed-dose oral steroids
    • Potentially life-threatening
    • Required radiotherapy with the past 28 days

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • Neutrophil count > 1,500/mm^3
  • Platelet count > 100,000/mm^3

Hepatic

  • AST and ALT < 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
  • Bilirubin < 1.5 times ULN
  • No hepatitis
  • No cirrhosis

Renal

  • Creatinine < 1.5 times ULN

Other

  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation
  • HIV negative
  • No preexisting neuropathy ≥ grade 2
  • No active or uncontrolled infection
  • No other serious illness or medical condition
  • No chronic alcohol abuse
  • No known hypersensitivity to systemic liposomal formulations or compounds chemically related to OSI-7904L or oxaliplatin
  • No prior psychiatric or neurologic condition that would preclude study compliance or giving informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • At least 21 days since prior immunotherapy
  • At least 21 days since prior monoclonal antibody therapy

Chemotherapy

  • See Disease Characteristics
  • At least 21 days since prior chemotherapy and recovered*
  • No prior oxaliplatin NOTE: *Alopecia allowed

Endocrine therapy

  • See Disease Characteristics
  • At least 21 days since prior hormonal therapy

Radiotherapy

  • See Disease Characteristics
  • At least 21 days since prior radiotherapy and recovered
  • No prior radiotherapy to more than 25% of bone marrow reserve

Surgery

  • Recovered from prior surgery

Other

  • At least 21 days since prior tyrosine kinase inhibitor therapy
  • More than 21 days since prior investigational agents
  • No other concurrent anticancer therapy
  • No other concurrent investigational agents
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   United Kingdom
 
 
NCT00081237
EORTC-16033
EORTC-16033
OSI-EORTC-16033
Not Provided
Not Provided
Not Provided
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Not Provided
Study Chair: Patrick Schoffski, MD, MPH Hannover Medical School
European Organisation for Research and Treatment of Cancer - EORTC
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP